Blue Trust Inc’s Nektar Therapeutics NKTR Stock Holding History

Blue Trust Inc’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-24	Closed	–	–	2534
2023 Q4	$0	Buy	+24	New	+$182	﹤0.01%	2632
2023 Q2	–	Sell	-4	Closed	–	–	2357
2023 Q1	$0	Sell	4 -2	-33%	-$61	﹤0.01%	2519
2022 Q4	$0	Sell	6 -12	-67%	-$581	﹤0.01%	2386
2022 Q3	$1K	Buy	18 +16	+800%	+$952	﹤0.01%	1967
2022 Q2	$0	Buy	+2	New	+$126	﹤0.01%	1964

Other funds holding NKTR

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Blue Trust Inc's NKTR Position: Q1 2024 in Review

Blue Trust Inc sold out of Nektar Therapeutics (NKTR) in Q1 2024, closing a stake of 24 shares.

Blue Trust Inc first reported a position in NKTR in Q2 2022 and held it in 5 quarters. The position peaked at $1K in Q3 2022. 124 funds tracked by Wall St. Rank hold NKTR as of Q1 2024.

Blue Trust Inc reported no remaining Nektar Therapeutics position as of Q1 2024 after selling out during the quarter.
Blue Trust Inc sold 24 Nektar Therapeutics shares in Q1 2024.
Blue Trust Inc first reported a position in Nektar Therapeutics in Q2 2022 and held it in 5 quarters.
Blue Trust Inc's Nektar Therapeutics position peaked at $1K in Q3 2022.
124 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2024.

Based on Blue Trust Inc's 13F filing for Q1 2024, filed 1 May 2024.